ArticleEuropean journal of nuclear medicine and molecular imaging2024
Image-based dosimetry for [
Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Predicting tumour and organ dose in α-radiopharmaceutical therapy: aEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Recent advances in PSMA therapy - from beta to alpha.Annals of nuclear medicine · 2026Review
- Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Review
- [International journal of molecular sciences · 2026Article
- State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies.Zeitschrift fur medizinische Physik · 2026Review
- PET-based risk stratification for adverse events under [European journal of nuclear medicine and molecular imaging · 2026Article
- Radiation Biology of Radiopharmaceuticals: Beyond External Beam Radiation Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Advancing towards cancer theragnostic by probing theCommunications medicine · 2026Article
- Recent advances and current landscape of software tools for image analysis and dosimetry in nuclear medicine.EJNMMI physics · 2026Review
- Review
- Emergence of a barium metal-organic framework for mitigating off-target effects of alpha radionuclide therapy.Theranostics · 2026Article
- Feasibility study ofEJNMMI physics · 2025Article
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Clinical perspective on targeted alpha therapy usingAnnals of nuclear medicine · 2025Review
- Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Comparison of scatter and partial volume correction techniques for quantitative SPECT imaging ofEJNMMI physics · 2025Article
- Gamma camera imaging characteristics ofEJNMMI physics · 2025Article
- Towards DFO*Pharmaceutics · 2025Article
- Survival impact of [European journal of nuclear medicine and molecular imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeAlthough
methodsFive patients (7.7 ± 0.2 MBq [
resultsMean kidney and lesion effective half-lives were as follows:
conclusionSPECT/CT imaging and urine analysis showed minor differences of up to 10% in the daughter-specific pharmacokinetics. These variances had a minimal impact on the lesion and kidney dosimetry which remained within 8%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.